Genzyme

Nanobiosym is an innovative company based in Cambridge, MA that specializes in the integration of physics, biomedicine, and nanotechnology to create groundbreaking technologies. Their mission is to address global health, energy, and environmental challenges by incubating and commercializing transformational technologies with game-changing impact. Through their Nanobiosym Diagnostics division, they have developed the Gene-RADAR, a portable nanotechnology platform that enables rapid and accurate detection of genetic fingerprints from any biological organism, providing affordable and accessible diagnostic information. With a focus on maximizing global humanitarian impact, Nanobiosym has spearheaded the Nanobiosym Global Initiative, collaborating with governments, NGOs, academia, and industry leaders to bring emerging technologies to tackle pressing global challenges. Led by Dr. Anita Goel, a renowned figure in biophysics and nano-biotechnology, Nanobiosym is at the forefront of the nanotechnology revolution, aiming to redefine the rules of medical diagnosis and contribute to the advancement of modern medicine.Generated from the website

Leap Therapeutics, based in Cambridge, MA, is dedicated to developing targeted and immuno-oncology therapeutics, with a focus on innovative treatments for various cancer types, including gastric, colorectal, and gynecologic cancers. Their lead candidate, DKN-01, is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein and is currently in clinical development for patients with DKK1-expressing tumors. In addition to DKN-01, Leap Therapeutics is advancing FL-301, which targets Claudin18.2 for gastric and pancreatic cancers, and FL-501, a preclinical candidate that targets the growth and differentiation factor 15 (GDF-15) protein. The company is committed to understanding tumor expression and discovering new therapeutic targets and combinations to improve cancer treatment outcomes. Generated from the website